Cargando…
GBT440 reverses sickling of sickled red blood cells under hypoxic conditions in vitro
Sickle cell disease is characterized by hemolytic anemia, vasoocclusion and early mortality. Polymerization of hemoglobin S followed by red blood cell sickling and subsequent vascular injury are key events in the pathogenesis of sickle cell disease. Sickled red blood cells are major contributors to...
Autores principales: | Dufu, Kobina, Oksenberg, Donna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036981/ https://www.ncbi.nlm.nih.gov/pubmed/30046411 http://dx.doi.org/10.4081/hr.2018.7419 |
Ejemplares similares
-
GBT440 Inhibits Sickling of Sickle Cell Trait Blood Under In Vitro Conditions Mimicking Strenuous Exercise
por: Dufu, Kobina, et al.
Publicado: (2016) -
Discovery of GBT440,
an Orally Bioavailable R-State
Stabilizer of Sickle Cell Hemoglobin
por: Metcalf, Brian, et al.
Publicado: (2017) -
The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia
por: Al Balushi, Halima, et al.
Publicado: (2019) -
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
por: Hutchaleelaha, Athiwat, et al.
Publicado: (2019) -
Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)